John Ansell, MBA
DirectorJohn Ansell Consultancy
John Ansell, BSc, MA, has been a pharmaceutical industry consultant since 1990, based in Thame, near Oxford, UK. He was employed for 20 years in the industry by Organon, Schering AG, Fisons, Solvay and Glaxo. His experience there and subsequently as a consultant is chiefly in business development, licensing, and international marketing. Mr. Ansell is the author of some 40 articles and reports on pharmaceutical issues, many for Decision Resources Inc. (www.johnansell.com), and has acted as chairman at over 30 pharma conferences. He is a frequent speaker on various aspects of pharma deals, as well as on marketing and R & D strategy. He was founding director of IBC/Falconbury's Pharma Executive Mini-MBA course (2005-). In the US, Mr. Ansell has been a member of the Editorial Advisory Board of Pharmaceutical Executive (1990-2002), and Chairman of the Advisory Board of Decision Resources since its inception (2005-). (This is me - Update Profile)
| 1990 - present | Director John Ansell Consultancy |
|---|
GLG Study Groups with John Ansell, MBA(?)
| Study Group Name | Members |
|---|---|
| Generic Drug Economic Experts | 666 |
| Generic Pharmaceuticals Economic Experts (Germany) | 42 |
GLG NewsSM Analyses by John Ansell, MBA(?)
As the biggest pharmaceutical company, Pfizer's R & D needs to be more productive than any other company's if it is to survive and prosper. But Pfizer must have new products that are big if they are to make an impact on its bottom line. The conundrum is that disease is a diffuse market, with...
In 1976, sitting in my office in International Marketing at Fisons, Loughborough, UK, I used to watch the drums of bulk paracetamol arriving at the factory from China - easily recognizable from the Chinese script decorating them. I'm sure the UK wasn't the only country importing raw materials from China...
European approval for Humira in psoriasis is a key step towards leadership over the other monoclonal antibodies already approved - and because this is the most valuable category, leadership also of the total psoriasis market. In April 2007 Abbott submitted this indication for approval to...
This move conforms with Lundbeck's strategy to concentrate on CNS areas and to bring in other parties to develop non-CNS applications.
GLG InstituteSM Seminars with John Ansell, MBA(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with John Ansell, MBA
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms